雷帕鸣治疗期间要注意什么呢？

/Rapamycin (sirolimus, Sirolimus, Rapamycin) was extracted by scientists in 1975 from Streptomyces hygroscopicus isolated from the soil of Easter Island, Chile.

Rapamycin is a new type of macrolide anti-rejection drug. It is the latest powerful immunosuppressant in the world. It is clinically used for anti-rejection of organ transplantation and the treatment of autoimmune diseases. Its immunosuppressive activity is dozens of times stronger than that of cyclosporine, which is currently widely used in clinical practice. It has low toxicity and small dosage. It also has a synergistic immunosuppressive effect with cyclosporine and is used clinically in combination with cyclosporine. Compared with cyclosporine and FK506, rapamycin is the least nephrotoxic immunosuppressant and has no neurotoxicity.  

Precautions for Rapamin: Patients with interstitial lung disease who receive immunosuppressive treatment (including Rapamin) may develop interstitial lung disease with no clear infectious agent, and some may be fatal. Such diseases include noninfectious pneumonia, bronchiolitis obliterans with organizing pneumonia (BOOP) (less frequently), and pulmonary fibrosis.

In some cases, stopping rapamycin or reducing the dose can eliminate this interstitial lung disease. As trough rapamin plasma concentrations increase, so does the risk of developing the disease. Latent Viral Infection Nephropathy and progressive multifocal leukoencephalopathy (PML) associated with BK virus have been observed in patients receiving immunosuppressives, including rapamycin. This infection can be associated with serious or fatal consequences, including kidney transplant failure. Hepatotoxicity: Hepatotoxicity has been reported, including fatal hepatic necrosis due to elevated trough sirolimus concentrations (i.e., above therapeutic levels). Poor healing has been reported after transplant surgery, including fascial dehiscence, incisional hernia, and rupture of anastomotic sites (such as wounds, blood vessels, airways, ureters, biliary tracts, etc.). Other clinical experience has reported the occurrence of azoospermia in patients receiving rapamycin, and most patients improved when rapamycin was discontinued. Clostridium difficile enterocolitis has been reported in patients receiving rapamycin.

The above are the precautions for taking it, I hope it can help everyone.